News | July 10, 2024
Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Ashkenazi will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee through July 2024
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
2024 full-year revenue guidance raised by US$ 2 billion
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant
The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
Innovent will supply sintilimab for the collaborated clinical trial
Subscribe To Our Newsletter & Stay Updated
